Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Development
Pharma
Eisai ends lorcaserin development in Dravet syndrome
In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor agonist lorcaserin.
Fraiser Kansteiner
Nov 18, 2024 10:18am
AstraZeneca trumpets new Calquence combos in CLL
Jul 29, 2024 10:25am
Nucleus RadioPharma unveils manufacturing pact with ARTBIO
May 7, 2024 8:47am
Cell therapy manufacturer Cellares draws $255M investment round
Aug 24, 2023 9:15am
Trial for controversial China-made Alzheimer's drug aborted
May 13, 2022 4:16pm
AZ, FibroGen clash on roxa's US path forward in CKD anemia
May 10, 2022 8:05am
